Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)

被引：0
|
作者：
Z. Wang
Z. Zhao
Y. Xia
Z. Cai
C. Wang
Y. Shen
R. Liu
H. Qin
J. Jia
G. Yuan
机构：
[1] Affiliated Hospital of Jiangsu University,Department of Endocrinology
来源：
Journal of Endocrinological Investigation | 2022年 / 45卷
关键词：
WGCNA; Single-cell RNA-seq; NASH; Fibrosis; HCC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1379 / 1392
页数：13
相关论文
共 50 条
  • [41] Noninvasive evaluation of nonalcoholic steatohepatitis (NASH)
    Mansour-Ghanaei, Fariborz
    Vahhabi-Moghaddam, Masrour
    Joukar, Farahnaz
    Asgharnezhad, Mehrnaz
    Kiyani, Noufar
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2013, 4 (04) : 797 - 798
  • [42] Nonalcoholic steatohepatitis (NASH): therapeutic approaches
    Buscher, HP
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 : S60 - S62
  • [43] Normal Weight Nonalcoholic Steatohepatitis (NASH)
    Samala, Niharika
    May, Kevin P.
    Kleiner, David E.
    Loomba, Rohit
    Terrault, Norah
    Neuschwander-Tetri, Brent A.
    Hoofnagle, Jay H.
    HEPATOLOGY, 2013, 58 : 495A - 495A
  • [44] Nonalcoholic steatohepatitis (NASH) drugs market
    Sorcha Cassidy
    Basharut A. Syed
    Nature Reviews Drug Discovery, 2016, 15 : 745 - 746
  • [45] Changes in GUT Microbiome Associated with Nash Progression in a Diet Induced Animal MODEL of Nonalcoholic Steatohepatitis (NASH)
    Amizadegan, Jasime
    Kashani, Mitra
    Gillevet, Patrick M.
    Sikaroodi, Masoumeh
    Marioneaux, Jonathon
    Nadler, Jerry
    Sanyal, Arun J.
    Caffrey, Rebecca
    HEPATOLOGY, 2018, 68 : 758A - 759A
  • [46] Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
    Caussy, Cyrielle
    Chuang, Jen-Chieh
    Billin, Andrew
    Hu, Tao
    Wang, Ya
    Subramanian, G. Mani
    Djedjos, C. Stephen
    Myers, Robert P.
    Dennis, Edward A.
    Loomba, Rohit
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [47] Molecular mechanisms of fibrosis progression in non-alcoholic steatohepatitis (NASH)
    Hellerbrand, C.
    LIVER CIRRHOSIS: FROM PATHOPHYSIOLOGY TO DISEASE MANAGEMENT, 2008, 162 : 75 - +
  • [48] A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis
    Li, Xuecheng
    Lu, Yi
    Liang, Xiaoshuang
    Zhou, Xiaofei
    Li, Dirui
    Zhang, Zan
    Niu, Yunchao
    Liu, Shuaishuai
    Ye, Ling
    Zhang, Rufeng
    PLOS ONE, 2023, 18 (05):
  • [49] Dietary docosahexaenoic acid (DHA) halts progression of nonalcoholic steatohepatitis (NASH), but does not promote fibrosis remission in Ldlr-/- mice
    Lytle, Kelli A.
    Wong, Carmen
    Jump, Donald
    FASEB JOURNAL, 2016, 30
  • [50] Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis
    Ratziu, V.
    Sanyal, A.
    Torres, D.
    Hinrichsen, H.
    Serfaty, L.
    Bambha, K.
    Jayakumar, S.
    Goodman, Z.
    Abdelmalek, M.
    Aguilar, R.
    Jia, C.
    Mccolgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Afdhal, N.
    Harrison, S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S594 - S595
12345